EU Contracts For A New 1 Million Mpox Doses... Still Way Behind, Globally... But Good News.

This is decidedly good news: the world's largest (by vials finished) manufacturer of vaccines, in India, has agreed to make up to one million doses of mpox vaccine, essentially immediately -- in a collabo to use new "container shells", from horsepox (just as the recombinant Covid vaccines used H1N1 "containers") -- in partnership with EU based Tonix. And yet, these totals will be well-short of the needed three million. But there will likely be contract extensions. So this is all positive.

And it likely means that Bavarian Nordic will be able to sell its fully-IP rights protected version -- for around $100 a vial in local US and EU and UK markets -- as a "reserve" stockpile, for those geographies. Maybe even parts of Central and South America, similarly. [Japan has a domestic production source.] Here's the latest:

. . .TNX-801 (recombinant horsepox virus) is a live replicating, attenuated virus vaccine based on horsepox in preclinical development to prevent mpox and smallpox.

TNX-801 is based on technology that has the potential to be used as a viral vector platform from which recombinant versions can be developed to protect against other infectious diseases, as well.

Bilthoven Biologicals is a global vaccine company that produces prophylactic and therapeutic use vaccines.

The European Union has selected Bilthoven Biologicals for its pandemic preparedness program of ‘ever warm’ vaccine manufacturing companies.

TNX-801 has demonstrated in animal models to provide immune protection with better tolerability than vaccines based on 20th-century vaccinia viruses.

Preclinical studies have shown positive efficacy data, demonstrating that TNX-801 protected non-human primates against lethal challenges with intratracheal Clade 1 mpox virus.

After a single dose vaccination, TNX-801 prevented clinical disease and lesions and decreased shedding in the mouth and lungs of non-human primates.

These findings are consistent with mucosal immunity and suggest the ability to block forward transmission. . . .

Onward smiling -- separately, time for the old annual physical, this aft. I don't think I've gained even two pounds, in 20 years. Hilarious.

नमस्ते